Pharmacokinetics of progesterone a few other countries under the brand name Progestasert. It was marketed between 1976 and 2001. The IUD was never widely used due to a relatively high contraceptive failure rate of 2.9% and the requirement of annual replacement. It contained 38 mg progesterone and released 65 μg progesterone into the uterus per day (adding up to about 35 mg after one year). For comparison, a woman's body produces on average about 25 mg progesterone per day during the luteal phase. While effective as a form of contraception and for decreasing menstrual bleeding and discomfort, long-lived IUDs can fundamentally only deliver
Pharmacokinetics of progesterone and has been found to result in higher serum peak progesterone levels relative to intramuscular oil formulations. In addition, subcutaneous injection of progesterone is considered to be easier, safer (less risk of injection site reactions), and less painful relative to intramuscular injection. The elimination half-life of this formulation is 13 to 18 hours, compared to 20 to 28 hours for intramuscular injection in oil. Progesterone has a very short elimination half-life of about 3 to 90 minutes when given by intravenous injection. A one-year progesterone intrauterine device (IUD) for hormonal birth control was previously available in the United States and